After several years with no new product launches, Merck KGAA is expected to announce imminently the EU filing for its much-delayed multiple sclerosis treatment cladribine, and will supplement this with another submission for its key immune-oncology offering, avelumab, later this year. However, further cladribine filings including in the US will await further discussions with regulators, with the company not prepared to share any timelines yet.
Speaking to analysts on June 20, Merck's chief marketing and strategy office for healthcare, Rehan Verjee, said that over the...